News

Ardelyx Inc (ARDX) reports significant revenue increases for IBSRELA and XPHOZAH, while navigating operational challenges and investing in future growth.

Moby summary of Ardelyx, Inc.'s Q1 2026 earnings call

Michael Raab: Thank you. At Ardelyx, we are building an innovative pipeline of medicines for patients with unmet medical needs. As we build on this momentum, our focus is on executing on our four key priorities: accelerating the growth of Ibsrela, maintaining the Exposa momentum, building and expanding our pipeline, and delivering strong financial results.

Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with “another significant year of growth” underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

If you are wondering whether Ardelyx at around US$5.95 is offering good value or asking too much, you are not alone. This article is built to help you frame that question clearly. The stock has seen mixed recent returns, with a 7.8% decline over the last 7 days, a 5.5% gain over 30 days, a 3.3% decline year to date, and a 13.1% return over the past year, which can change how you think about both risk and opportunity. Recent attention on Ardelyx has focused on how its pipeline, regulatory...

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wondering if Ardelyx at around US$5.94 is offering real value or just headline noise? This article walks you through what the numbers are actually saying about the stock. The share price return sits at 8.4% over the last 7 days. The 30-day and year-to-date returns are a 5.3% decline and a 3.4% decline respectively, set against a 30.5% gain over the past year and a 35.0% return over 3 years, with a 20.2% decline across 5 years. Recent moves come against a backdrop of ongoing interest in...